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Abstract
Background: The overlapping geographical and socio-economic distribution of malaria and
helminth infection has led to several studies investigating the immunological and pathological
interactions of these parasites. This study focuses on the effect of treating schistosome infections
on natural human immune responses directed against plasmodia merozoite surface proteins MSP-
1 (DPKMWR, MSP119), and MSP-2 (CH150 and Dd2) which are potential vaccine candidates as well
as crude malaria (schizont) and schistosome (whole worm homogenate) proteins.
Methods: IgG1 and IgG3 antibody responses directed against Schistosoma haematobium crude adult
worm antigen (WWH) and Plasmodium falciparum antigens (merozoite surface proteins 1/2 and
schizont extract), were measured by enzyme linked immunosorbent assay (ELISA) in 117
Zimbabweans (6–18 years old) exposed to S. haematobium and P. falciparum infection. These
responses were measured before and after anti-helminth treatment with praziquantel to determine
the effects of treatment on anti-plasmodial/schistosome responses.
Results: There were no significant associations between antibody responses (IgG1/IgG3) directed
against P. falciparum and schistosomes before treatment. Six weeks after schistosome treatment
there were significant changes in levels of IgG1 directed against schistosome crude antigens,
plasmodia crude antigens, MSP-119, MSP-2 (Dd2), and in IgG3 directed against MSP-119. However,
only changes in anti-schistosome IgG1 were attributable to the anti-helminth treatment.
Conclusion: There was no association between anti-P. falciparum and S. haematobium antibody
responses in this population and anti-helminth treatment affected only anti-schistosome responses
and not responses against plasmodia crude antigens or MSP-1 and -2 vaccine candidates.
Background
Every 40 seconds a child dies of malaria, a total of more
than 2000 deaths per day, [1]. Malaria is the most impor-
tant human parasitic disease in terms of deaths, clinical
cases and long term consequences for affected communi-
ties. In contrast, schistosomiasis is responsible for rela-
tively few deaths, but is associated with considerable
morbidity. About 200 million people are currently
thought to be infected, with a further 600 million at risk
of infection [2]. The geographical and socio-economic
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with that of many helminth infections including Schisto-
soma haematobium in sub-Saharan Africa. This gives poten-
tial for interaction in the overall susceptibility, pathology
or clinical manifestations for these infections. Indeed
there is now a growing body of evidence showing that in
both natural and experimental infections, schistosome
and plasmodia infections profoundly affect each other
immunologically and in the degree of pathology they
cause in the host. Several studies have reported both cel-
lular and humoral immunological interactions between
plasmodia and schistosome infection [3-6] which may
partly be explained by the existence of cross reactive
epitopes between schistosome and plasmodia antigens
[7,8].
We are interested in the potential effect of schistosome
control programmes on malaria vaccine efficacy. Schisto-
some infection is controlled by treatment of infected peo-
ple with the anti-helminth drug praziquantel and we have
previously shown that treating S. haematobium infection
alters schistosome specific humoral and cellular
responses, accelerating the development of these
responses [9,10]. We have subsequently shown that this
modulation of immune responses is related to a change in
both the quantity and type of antigens recognized by the
host's immune system [11]. Since praziquantel treatment
is used in people exposed to both malaria and schisto-
somiasis, it is important to determine if this chemother-
apy alters any of the responses to malaria vaccine
candidate antigens and therefore inadvertently affects
their use for vaccination. Therefore, the aim of this study
is to determine whether praziquantel treatment for schis-
tosomiasis modulates natural antibody responses to
malaria vaccine candidate merozoite surface proteins
[12,13]. We focuses on IgG1 and IgG3 immune responses
associated with protection against these antigens [12,14].
Methods
Parasite antigens
Lyophilized soluble S. haematobium adult worm antigen
(SWAP) was obtained from the Theodor Bilharz Institute
(Egypt) and reconstituted as previously described else-
where [11]. The parasite strain is one used for previous
immuno-epidemiology studies [15]. Crude P. falciparum
schizont antigen preparations were a gift of Dr. P. Druilhe,
Institute Pasteur, Paris. The merozoite surface protein
antigens used were prepared as recombinant proteins in
Escherichia coli. Two antigens derived from merozoite sur-
face protein 1 (MSP-1), DPKMWR and MSP-119 antigens
also known as p190, gp195, [16] were used. MSP-1 can be
divided into 17 distinct blocks, based on its conserved,
semi-conserved and variable regions. Block 2 is highly
polymorphic, with over 50 sequences described. However
these sequences fall into one of 3 categories or serotypes:
K1; Mad20; and RO33 [17] and DPKMWR is a recom-
binant protein composed of Block 2 sequences from all 3
block 2 serotypes. MSP-119 is the conserved C terminal of
MSP-1, and is the only part to remain on the surface of the
merozoite, with the rest of the protein being shed upon
erythrocyte invasion. Two full-length recombinant MSP-2
antigens were also used, namely CH150/9 (5/6) and Dd2
(13/14). MSP-2 has 2 serotypes: CH150/9 5/6 is taken
from serotype A (3D7-like), and Dd2 belongs to serotype
B (FC27-like).
Study population and sample collection
The study was conducted in the Mashonaland East Prov-
ince of Zimbabwe (31°30'E; 17°45'S) where S. haemato-
bium and P. falciparum are endemic. The study area is
described in detail elsewhere [18]. Briefly the area is rural
with the majority of the people living in thatched houses
made up of clay. The main activity in these villages is sub-
sistence farming and human water contact is frequent
with at least 4 contacts/person/week due to insufficient
safe drinking water and sanitation facilities (see [18] for
studies in neighboring villages). Drinking water is col-
lected from open wells while bathing and washing is con-
ducted in two main rivers in the villages. Most families
maintain a garden located near the river where water is
collected for watering the crops. The villages were selected
because health surveys regularly conducted in the region
by the Provincial Medical Director showed little or no
infection with other helminths and a low S. mansoni prev-
alence (<5%). Permission to conduct the work in this
province was obtained from the Provincial Medical Direc-
tor and ethical approval received from the Medical
Research Council of Zimbabwe http://www.afronets.org/
guidelines_for_researchers_and_ethics_committees.pdf.
Informed consent (following explanation of the study
aims and procedures) was obtained before the collection
of parasitology and blood samples. The selected villages
had not been included in the National Schistosome Con-
trol Program and there were no active malaria vector con-
trol programmes in the area. Therefore participants had
not received treatment for schistosomiasis or other
helminth infections meaning that we could study natural
immune responses in the absence of drug-altered schisto-
some responses [9,19].
Plasmodium falciparum is the predominant species of
malaria in Zimbabwe [20] where malaria transmission is
largely unstable in nature. Approximately 5.5 million peo-
ple out of a total population of 12.7 million live in malar-
ious areas [21]. Out of the 56 districts in Zimbabwe,
malaria transmission occurs in 42. In 2002, a revised strat-
ification based on a national parasite prevalence survey,
HMIS data, entomological data and expert opinion was
prepared which classified our study area under the spo-
radic transmission regions with low transmission [21-23]Page 2 of 13
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The peak P. falciparum transmission occurs from February
to May [24] and our sampling times were in March and
then 6 weeks later in April. The schools surveyed (a sec-
ondary school and its feeder primary school (i.e. where
the majority of the primary school children come from)
Goromonzi and Shangure Schools in Village, and
Chindenga and Nyambanje Schools in Mutoko Village)
were all in close proximity to rivers. Stool and urine spec-
imens were assayed for S. haematobium, S. mansoni and
geo-helminths using standard procedures [25,26] and the
intensities of S. haematobium calculated from at least 2
urine samples (maximum 3) collected on consecutive
days, and those of S. mansoni calculated from mean inten-
sities of at least 4 Kato-Katz slides (maximum 6), 2 from
each of the 2–3 stool samples collected. Anti-helminth
treatment was administered to all compliant people after
the first survey as well as 6 weeks later at the end of the
study. In order to be included in the cohort, participants
had to meet all the following criteria at the two sampling
points (pretreatment and 6 weeks post-treatment): 1)
have provided at least 2 urine and 2 stool samples on 3
consecutive days which are used for S. haematobium and
intestinal helminths detection including S. mansoni; 2) be
negative for intestinal helminths including S. mansoni (no
one was excluded on this criteria as everyone was negative
for these infections), 3) be negative for schistosome infec-
tion at the 6 week survey if they had received ant-helminth
treatment, 4) have given at least 10 mls of blood for sero-
logical assays and preparation of a thick smear slide for
microscopic detection of Plasmodium parasites. 117 peo-
ple (53 male, 64 female) aged between 6–18 years old met
these criteria and were included in the study. Of these, 89
people received praziquantel treatment while 28 people
were not treated either because they did not take western
medicine for religious reasons (23) or were not present on
treatment days. The 28 people agreed to take part in the
study and effectively became untreated controls. Thus the
population was stratified by its schistosome and malaria
staus as well as schistosome treatment history as shown in
table 1. People presenting with malaria were treated
according to the treatment regime prescribed by the Min-
istry of Health in Zimbabwe.
Immunological assays
The antibody subclasses associated with protection
against the MSP antigens are IgG1 and IgG3 [12,14]. Stud-
ies in S. haematobium have also associated IgG1 and IgG3
subclasses with protection against schistosomiasis [9,27].
Therefore this study focused on these two responses
directed against crude schistosome worm antigen
(WWH), crude malaria schizont and MSP-1/2 antigens.
Indirect enzyme linked immunosorbent assays (ELISA)
already published for S. haematobium [15] and for the P.
falciparum antigens [28-30] were used for the assays.
Briefly, ELISAs were conducted in duplicate for each sam-
ple using ELISA plates (Nunc-Immulon, Denmark) that
were coated with 50 ul/well of 50 ng/ml antigen for
recombinant antigens and 1 ug/ml for both crude anti-
gens in 60 mM carbonate-bicarbonate buffer (pH 9.6)
and incubated overnight at 4°C. Plates were blocked with
200 μl/well of skimmed milk (5% milk in phosphate
buffered saline (PBS)/0.03% Tween 20) for 1 hr and
washed three times in PBS/Tween 20, which was used for
all washes. 100 μl of serum was added to each well at
1:100 dilution for all assays except for MSP119 which was
1:200; plates were incubated overnight at 4°C and then
washed three times. 100 μl of subclass-specific mono-
clonal antibody was added at 1:1000 dilution for the
detection of IgG1 and IgG3 (The Binding Site, UK). Plates
were incubated overnight at 4°C, washed six times and
100 μl of ABTS substrate solution (KPL, Canada) was
added, before the absorbance was read at 405 nm. Three
negative controls from European volunteers who had
never traveled to malaria or schistosome endemic areas
were used on each plate and people were considered reac-
tive if they had an absorbance value greater than the mean
plus 2 standard deviations of the negative controls.
Statistical analysis
Statistical analyses were conducted using the statistical
package SPSS and were used to test three distinct hypoth-
eses, 1) P. falciparum status is not associated with schisto-
some-specific responses or schistosome infection level, 2)
schistosome infection intensity is not related to plasmo-
dia-specific responses or P. falciparum status, 3) treatment
of schistosome-infected people with praziquantel does
not affect plasmodia-specific responses.
For all statistical analyses, participants were divided into
three age groups, 6–11 years old, 12–13 years, 14–18
years old reflecting the epidemiological groupings where
schistosome infection levels are rising, peaking and
declining as well as give large enough sample sizes for the
statistical analyses. The initial statistical procedure was
conducted to reduce the number of variables used in
hypothesis testing. Partial correlation analysis was used to
explore correlations between antibody levels directed
against schistosome and plasmodia antigens. This was fol-
lowed by factor analysis using principal components
(PCA) [31]. PCA is a standard technique for reducing mul-
tivariate data down to its main independent features [31].
Components are extracted according to the amount of
variation in the data they explain so the first component
explains the most variation and each subsequent compo-
nent is included if it explains a significant amount of var-
iation present with the data [32]. This procedure was used
in this instance for two reasons (1) to avoid type I and
type II errors in multiple tests and using correlated inde-
pendent variables [33,34] and (2) to determine if anti-Page 3 of 13
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arately. Following the factor analysis principal compo-
nents were analyzed further with logistic regression to
determine the risk factors associated with being infected
with malaria to specifically address hypothesis 1. The PCA
were also used in an analysis of variance (ANOVA) to
address hypothesis 2. For this analysis the following vari-
ables were categorical; sex (male, female); age (3 catego-
ries already described); malaria status (positive, negative)
and the PCA factors 1 and 2 as continuous variables.
Schistosome infection intensity (log (x+1) transformed)
as the dependent variable.
To test the effects of treatment on immune responses it
was necessary to first establish if there had been a signifi-
cant change in antibody responses between the two time
points. A non parametric 2-tailed Wilcoxon test for related
samples was used for this analysis since antibody levels
were not normally distributed. This was followed by an
analysis determining if the observed differences were asso-
ciated with praziquantel treatment, comparing the change
in treated vs. untreated people after allowing for the
effects of host sex, age, pre-treatment schistosome infec-
tion intensity and pre-treatment malaria infection status
using repeated measures ANOVA. All statistical analyses
were performed using the statistical software SPSS, and
type III sums of squares were used to calculate the F-value
where appropriate and the p value was set at 0.05 (see
[33]). Unless otherwise stated, all statistical procedures
used the following variables as categorical; sex (male,
female); age (3 categories already described); malaria sta-
tus (positive, negative); and schistosome treatment
(treated, untreated). The following variables were contin-
uous; mean schistosome infection intensity (log10 (x+1)
transformed), antibody level (absorbance at 405 nm) and
the principle components.
Results
Schistosome epidemiology
Parasitological examination gave an overall schistosome
infection prevalence of 59% and a mean infection inten-
sity of 39 eggs/10 ml of urine (SE = 11 with a range
between 0 and 1000 eggs) before praziquantel treatment.
Infection prevalence and intensity followed a convex age-
infection profile with infection levels rising to peak in
children 12–13 years old and infection intensity declining
faster than infection prevalence thereafter (Figure 1).
Eighty-nine people received praziquantel treatment and
28 were not treated. The prevalence of schistosome infec-
tion in this group did not differ significantly (57% and
60% respectively), but infection intensity was higher in
the treated group (45 vs. 19 eggs/10 ml urine). This differ-
ence was accounted for by allowing for the effects of infec-
tion intensity before testing for the effects of treatment on
the change in antibody level in the statistical analyses. All
participants except 1 showed a detectable anti-schisto-
some antibody response.
Plasmodium epidemiology
Malaria infection as determined by microscopic examina-
tion of thick smear slides was P. falciparum and had a prev-
alence of 66%. Parasite densities were not determined. P.
falciparum prevalence peaked earlier (in 6–11 year olds)
than schistosome prevalence (Figure 2) and did not differ
significantly between people who received anti-helminth
treatment and those who remained untreated (65% and
68% respectively). P. falciparum positive participants were
parasitemic but asymptomatic and none of the partici-
S. haematobium infection intensity (mean of the age group) and prevalence for the different age groupsFigur  1
S. haematobiuminfection intensity (mean of the age 
group) and prevalence for the different age groups. 
Infection rises with age peaking in 12–13 year olds. Bars rep-
resent standard error of the mean.
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tion or were treated for malaria in between sampling
times. There was no significant change in P. falciparum
prevalence between the two sampling time points (66%
vs. 62%) but a few people moved between infection sta-
tus; 36 people remained negative, 68 positive while 9 peo-
ple changed status from positive to negative and 4 from
negative to positive. All participants except 3 had a detect-
able IgG3 response to P. falciparum schizont antigen a
marker for relative exposure levels to P. falciparum infec-
tion [35] and these 3 did have a detectable IgG1 response
against this antigen. For all antigens (plasmodia and
schistosome specific), the most prevalent response was
IgG3 and this showed different patterns with age to the
IgG1 (Figures 3 and 4).
Immune responses before treatment
The participants mounted immune responses to both
plasmodia and schistosome antigens as shown in Figures
3 and 4. There were no significant differences in responses
between the two groups (those to receive treatment and
those to remain untreated) at the beginning of the study
before anti-helminth treatment (Figures 5 and 6). When
measuring the levels of antibody responses, those directed
against the schistosome whole worm crude antigen were
predominantly IgG1 while the responses to malaria sch-
izont antigen were mixed both before treatment and 6
weeks later. Responses to the MSP-1 antigens were pre-
dominantly IgG1 and while those directed against the
MSP-2 antigens were mixed.
Initial partial correlation analyses controlling for sex, age,
malaria status and pre-treatment schistosome infection
intensity showed no significant correlations between anti-
plasmodial and anti-schistosome responses. This was con-
firmed by factor analysis which reduced the 12 antibody
responses (IgG1 and IgG3 directed against the 6 antigens;
WWH, schizont, MSP-1 antigens (DPKMWR, MSP-119),
MSP-2 antigens (CH150 and Dd2) into two components
partitioned by parasite species with all the anti-plasmo-
Percentage of people producing detectable IgG1 antibodies against the antigens schistosome WWH (diamond), MSP-2 (CH150)(squares), MSP-2(Dd2)(triangles), MSP (DPK) (crosses), MSP-1(19) (stars) and P. falciparum schizont (circles)Figure 3
Percentage of people producing detectable IgG1 antibodies against the antigens schistosome WWH (dia-
mond), MSP-2 (CH150)(squares), MSP-2(Dd2)(triangles), MSP1(DPK) (crosses), MSP-1(19) (stars) and P. falci-
parum schizont (circles).
MSP-2(ch150)IgG1  
WWHIgG1
MSP-1(19)IgG1
MSP-1(DPK)IgG1Page 5 of 13
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two anti-schistosome responses falling in a separate com-
ponent (PCA2) as shown in Table 2. The next step was to
determine if these two variables representing anti-schisto-
some and anti-plasmodial responses affected the risk of a
person being positive for malaria infection. This was con-
ducted using a logistic regression which included host age,
sex and schistosome infection intensity. This analysis
showed that host sex, age and of level of anti-plasmodial/
schistosome antibodies did not affect the risk of P. falci-
parum infection. However, schistosome infection intensity
was a significant risk factor with the likelihood of being
parasitemic for P. falciparum increasing with increasing
schistosome infection intensity (B = 0.589, SE = 0.270,
Wald = 4.77, df = 1, p = 0.029). Conversely schistosome
infection intensity was significantly higher in people who
were parasitemic for P. falciparum (F = 5, 67, df = 1, 117,
p = 0.019) and was positively associated with PCA2 (F =
21.5, df = 1,117, p < 0.001). The later means that schisto-
some infection intensity increased with increasing levels
of anti-WWH IgG1 and IgG3. There was no significant
association between anti-plasmodial responses (PCA1)
and schistosome infection intensity (F= 0.002, df = 1, 117,
p = 0.969).
Effect of treatment on anti-schistosome and anti-
plasmodial IgG1 and IgG3 responses
Six weeks after treatment of schistosome infections with
the drug praziquantel, anti-schistosome and anti-plasmo-
dial responses were assessed again to determine the fac-
tors associated with the change in the levels of these
responses. There were significant changes in levels of IgG1
directed against WWH, MSP-2 (Dd2), MSP-119 and sch-
izont antigen (Table 3) and in IgG3 directed against MSP-
119. Where significant changes occurred, for them to be
associated with praziquantel treatment, they had to differ
significantly between praziquantel-treated people and the
untreated controls after allowing for all other confound-
Percentage of people producing detectable IgG3 antibodies against the antigens schistosome WWH (diamond), MSP-2 (CH150)(squares), MSP-2(Dd2)(triangles), MSP1(DPK) (crosses), MSP-1(19) (stars) and P. falciparum schizont (circles)Figure 4
Percentage of people producing detectable IgG3 antibodies against the antigens schistosome WWH (dia-
mond), MSP-2 (CH150)(squares), MSP-2(Dd2)(triangles), MSP1(DPK) (crosses), MSP-1(19) (stars) and P. falci-
parum schizont (circles).
MSP-2(ch150)IgG3  
WWHIgG3
MSP-1(19)IgG3
MSP-1(DPK)IgG3
MSP-2(Dd2)IgG3
SchizontIgG3Page 6 of 13
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ment schistosome infection intensity). Only changes in
anti-schistosome IgG1 differed significantly between
treated and untreated people (Table 3), declining in
untreated people, while increasing in treated people (Fig-
ures 7 and 8).
Discussion
The overlapping geographical and socio-economic distri-
bution of P. falciparum and helminth infections has led to
studies investigating the immunological and pathological
interactions of these parasites some of which have
reported the presence of cross reactive antigens between
schistosome and malaria parasites (see [7] for review).
There are also several studies which have reported that
treatment of schistosome-infected/exposed people with
the anti-helminth drug praziquantel alters their immune
responses (see [36] for review). Given that there are now
several control programmes distributing praziquantel in
mass treatment programmes in Africa such as those con-
ducted by the Schistosome Control Initiative http://
www.schisto.org/, it is vital to determine if such treatment
has an impact on natural immune responses directed
against malaria vaccine candidates.
In this study IgG1 and IgG3 responses directed against S.
haematobium and P. falciparum antigens were studied
before and after anti-helminth treatment with praziquan-
tel. The presence of antibody responses to both P. falci-
parum and schistosome crude antigens (except one person
who showed no reaction to schistosome antigens) indi-
cated that the participants had been exposed to the infec-
tions and the IgG subclass responses to both parasites
were largely in agreement with previously published
results. The predominant response to schistosome crude
antigens was IgG1 which is consistent with studies in
other Zimbabwean populations [15]. Mixed IgG1 and
IgG3 responses to plasmodia MSP-2 such as those
observed here are common in semi-immune or non-
immune cohorts [37]. Responses to the N-terminal Block
2 region of MSP-1 are predominately of the IgG3 subclass,
so the mixed responses to the DPK antigen are unusual;
this might be explained by the fact that the DPK antigen
also includes the Block 1 region of MSP-1 [38], for which
Mean IgG1 and IgG3 antibody responses directed against P. falciparum and schistosome antigens in the group not receiving anti-helminth treatment at the 2 time intsFigure 5
Mean IgG1 and IgG3 antibody responses directed against P. falciparum and schistosome antigens in the group 
not receiving anti-helminth treatment at the 2 time points. Bars represent standard error of the mean. Light histo-
grams represent antibody levels at the start of the study, dark histograms antibody values 6 weeks later.Page 7 of 13
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BMC Infectious Diseases 2008, 8:158 http://www.biomedcentral.com/1471-2334/8/158previous antibody isotype analysis is not available. As
reported in other studies, the subclass response to MSP-
119 was biased towards IgG1, with a minor component
from the IgG3 subclass [39,40].
In this study the anti-plasmodial responses were not
related to the schistosome responses. We and other
groups have previously reported correlations between P.
falciparum and schistosome immune responses. Our pre-
vious work suggested that there was an association
between immune responses directed against crude anti-
gens from the parasites [41], while Naus et al reported
cross reactivity between IgG3 directed against P. falci-
parum MSP-2 and S. mansoni adult worm antigens in peo-
ple exposed to both parasites [8]. They suggested that
rather than having cross-reactive epitopes the two anti-
gens might have molecules such as lectins that are cross-
reactive. In this current study we found no association
between anti-schistosome WWH and anti- MSP-2
responses. The differences in our results and those previ-
ously reported may be due to use of specific defined anti-
gens as opposed to crude antigens [41]. In cases where
defined single antigens have been used [8], the difference
in our results may be due to genetic differences in the Plas-
modium parasite strains which may differ in the repeat
sequences of the two MSP-2 antigens used [42,43]. We
also showed no association between responses against
MSP-1 and schistosome adult worms. This, together with
our previous study showing that there was no association
between schistosome-specific antibodies with responses
directed against MSP-3b [41], suggests that there may not
be any cross-reactive epitopes between these P. falciparum
MSP proteins and schistosome crude antigens. This study
showed that the anti-plasmodial responses did not affect
Mean IgG1 and IgG3 antibody responses directed against P. falciparum and schistosome antigens in the group receiving anti-helminth treatment at the 2 tim  ints (i.e. pr - and post-treatment)Figure 6
Mean IgG1 and IgG3 antibody responses directed against P. falciparum and schistosome antigens in the group 
receiving anti-helminth treatment at the 2 time points (i.e. pre- and post-treatment). Bars represent standard 
error of the mean. Light histograms represent antibody levels at the start of the study, dark histograms antibody values 6 
weeks later (after praziquantel treatment).Page 8 of 13
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ies relating the level of P. falciparum parasitemia to these
responses are needed to determine if their effect is quanti-
tative rather than qualitative. The oberservation that schis-
tosome infection intensity was a significant risk factor for
being P. falciparum positive with the likelihood of having
malaria increasing with increasing schistosome infection
intensity is consistent with findings from other studies
[44]. The reason for this association is yet to be elucidated
and may include several factors such as host genetics, host
exposure patterns and parasite biology.
Anti-helminth treatment increased the level of the anti-
schistosome IgG1 response. Although this increase in
IgG1 is marginally significant (p = 0.046), it is consistent
with previous reports [9] and is not surprising as praziqu-
antel treatment introduces a large amount of parasite anti-
gens to the host simultaneously [45]. In a previous study
we reported that there were significant changes in
responses directed against MSP-3b and Glutamate Rich
Protein (Glurp R0) following praziquantel treatment, but
we could not attribute this change to the anti-helminth
treatment due to lack of untreated controls in the study
[41]. In this current study we were able to include a group
of untreated people so that we could explicitly test the
effects of treatment on plasmodia and schistosome-spe-
cific responses and although there were significant
changes in the anti-plasmodial responses none of these
Table 2: Results of the Factor Analysis using Principle Components giving the loadings of each antibody response in each component.
Principle Component 1 (anti-plasmodial responses) Principle Component 2 (anti-schistosome responses)
Initial Eigen values % variance 46.465 13.241
Variables Loadings Loadings
WWH-IgG1 0.08 0.796
WWH-IgG3 -0.011 0.879
MSP-2 (CH150)-IgG1 0.864 -0.064
MSP-2 (CH150)-IgG3 0.715 0.101
MSP-2 (Dd2)-IgG1 0.740 -0.001
MSP-2 (Dd2)-IgG3 0.857 -0.30
MSP-1 (DPK)-IgG1 0.615 -0.304
MSP-1 (DPK)-IgG3 0.662 0.216
MSP-1 (MSP119)-IgG1 0.682 -0.2
MSP-1 (MSP119)-IgG3 0.876 -0.043
Schizont-IgG1 0.697 0.028
Schisont-IgG3 0.704 0.211
Principle Component 1 (PCA1) is most influenced by the anti-plasmodial responses while PCA2 is most influenced by anti-schistosome responses. 
The loadings indicate the correlation between the original variable and the new principle competent (PC), i.e. they indicate the extent to which the 
original variables are influential in forming the PC [32]. Variables with loadings > 0.5 are highlighted in bold.
Table 3: Results of the statistical tests determining if there was a significant change in antibody level between the two time points (pre 
and post-treatment) and subsequently if any significant changes were related to praziquantel treatment
T-test Multi-variate analysis
Response Z-value P-value (2 tailed) F-value P-value
WWH-IgG1 -3.424 0.001 4.083 0.046
WWH-IgG3 -1.206 0.228 0.054 0.816
MSP2 (CH150)-IgG1 -0.927 0.354 0.012 0.914
MSP2 (CH150)-IgG3 -1.658 0.098 0.068 0.974
MSP2 (Dd2)-IgG1 -3.386 0.001 0.135 0.714
MSP2 (Dd2)-IgG3 -0.895 0.371 0.849 0.359
MSP1 (DPK)-IgG1 -0.738 0.460 0.094 0.760
MSP1 (DPK)-IgG3 -1.885 0.059 0.676 0.413
MSP1 (MSP119)-IgG1 -3.292 0.001 0.524 0.471
MSP1 (MSP119)-IgG3 -3.927 0.000 0.069 0.793
Schizont-IgG1 -2.342 0.019 0.018 0.894
Schizont-IgG3 -0.970 0.332 0.227 0.635
A 2-tailed Wilcoxon nonparametric test for related samples was used to determining if there was a difference between the two time points 
(antibody data were not normally distributed even after transformations). A multi-variate analysis of variance was used to determined if any 
significant differences between the two time points were related to treatment. Residuals from this parametric test were normally distributed. The 
degrees of freedom for this were 1 and 117. For both tests P-values < 0.05 are highlighted in bold.Page 9 of 13
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possible explanation for the changes in the plasmodia
responses over the 6 weeks could be related to the dynam-
ics of the P. falciparum infection in the study population.
Generally levels of IgG1 declined over the 6 weeks while
IgG3 levels rose. A recent study in Kenyan children
reported that the anti-plasmodial IgG1 and IgG3
responses to MSP-1 and MSP-2 antigens had a short half
life with changes detectable within 6 week [46]. In the
Kenyan study, levels of antibodies declined after a malaria
attack unless they were boosted by the appearance of plas-
modia parasites in the blood. In our study most children
who were parasitemic at the beginning of the study were
also parasitemic at the 6 week time point so that the anti-
gen challenge was present at the two time points. This
would have resulted in the maintenance of responses to
Table 1: Sample sizes of the population classified by schistosome and P. falciparum infection status
Praziquantel Treated Untreated controls
P. falciparum parasitemia 
positive
P. falciparum parasitemia 
negative
P. falciparum parasitemia 
positive
P. falciparum parasitemia 
negative
S. haematobium egg 
positive
36 17 11 5
S. haematobium egg 
positive
22 14 8 4
Changes in IgG1 responses directed against schistosome and P. falciparum antigensFigur  7
Changes in IgG1 responses directed against schistosome and P. falciparum antigens. Since these are obtained by 
subtracting post-treatment levels from pre-treatment levels, increases in antibody levels after the 6 weeks appear on the nega-
tive scale, while decreases appear on the positive scale. * represents a significant difference between praziquantel-treated and 
untreated people at p < 0.05. Bars represent standard error of the mean. Light histograms represent untreated participants, 
dark histograms represent untreated participants.Page 10 of 13
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BMC Infectious Diseases 2008, 8:158 http://www.biomedcentral.com/1471-2334/8/158the antigens and may be indicating the previously pub-
lished shift from IgG1 to IgG3 responses directed against
merozoite surface proteins [37]. Given the mesondemic
transmission patterns of the region, full interpretation of
the treatment-independent changes requires quantitative
studies enumerating the parasites as well as genotyping
studies indicating infection/re-infection episodes in the
intervening time. However since there were no significant
differences attributable to praziquantel treatment in the
participants it can be concluded that anti-helminth treat-
ment of people exposed to both P. falciparum and S. hae-
matobium parasites did not affect antibody responses
against the MSP-1 and -2 malaria vaccine candidates. Fur-
ther studies in a younger age group (children below 5
years of age, (who may be the main vaccine target group
http://www.malariavaccine.org/about-goals.php) over a
longer period will be valuable in developing integrated
malaria and schistosome control programmes.
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